Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2012

View Archived Issues

Otsuka Pharmaceutical reports new candidate cancer therapies

Novel inhibitors of diacylglycerol O-acyltransferase 1 presented

Abbott designs novel focal adhesion kinase 1 inhibitors

AstraZeneca scientists discover novel plasminogen inhibitors

New sodium channel antagonists described

Hepatitis C vaccine shows promise in proof-of-concept trial

BRISK PS trial compares brivanib to placebo in liver cancer

Phase II data presented on ACE-031 in boys with Duchenne's muscular dystrophy

Doxapram enantiomer retains respiratory stimulant properties without adverse effects

Novel multikinase inhibitor is active in FLT3-dependent leukemia cells

Isis begins phase II ISIS-APOCIIIRx study

Genfit reports on GFT-505 study in NAFLD/NASH

Gentium receives day 180 list from EMA for defibrotide MAA

Sato Pharmaceutical set to launch anesthetic cream in Japan

FDA approves expanded dose range for schizophrenia drug

Pfizer stops phase III study of Lyrica

Phase III study of hydroxychloroquine begins in Japan

Abbott to acquire melanocortin receptor agonist

MediGene receives final milestone payment for Eligard

Pfizer offers overview of first quarter 2012

Exelixis expands cabozantinib development program

Oncolytics Biotech enters into agreement for phase II Reolysin study

NIH launches program providing researchers access to industry compounds

Phase IIIb trial of Lyrica does not meet primary endpoint

Roche terminates development of antidyslipidemia drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.